Tsubota Laboratory Incorporated [4890.T]
TOKYO, Jun 01 (Pulse News Wire) – Tsubota Laboratory Incorporated (4890.T) announced today that its board of directors approved the acquisition of Mediproduces Co., Ltd. on June 01, 2026.
The deal involves purchasing all shares of Mediproduces, making it a subsidiary effective July 01, 2026. Mediproduces, founded in August 2005, specializes in medical marketing PR, healthcare events, and cosmetics development. With this acquisition, Tsubota Lab aims to enhance its cross-sector portfolio, leverage sales synergies in cosmetic products, accelerate research outcomes through medical network utilization, and strengthen its financial base. The transaction includes advisory fees totaling approximately ¥1 billion.
Key details of the acquisition include: - Number of shares acquired: 100,000 - Total cost: Approximately ¥1 billion - Pre-acquisition shareholding: 0 shares (0 voting rights / 0% ownership) - Post-acquisition shareholding: 100,000 shares (100,000 voting rights / 100% ownership) Independent valuation was conducted within the range determined by an external appraisal firm. The move follows due diligence procedures to ensure fairness and transparency, involving independent advisors and external experts for financial and tax reviews. In the fiscal year ending March 2027, Mediproduces' performance will be reflected in Tsubota Lab's consolidated results starting from the second quarter. Further impacts on Tsubota Lab’s earnings for the fiscal year ending March 2027 are currently being assessed and will be disclosed promptly if significant changes occur.
🟡 Confidence: Standard AI-translated content.